Ligand Pharmaceuticals IncorporatedLGNDNASDAQ
LOADING
|||
Year-over-year gross profit growth rate
| Period | Value |
|---|---|
| Q3 2025 | 102.69% |
| Q2 2025 | 10.46% |
| Q1 2025 | 1.27% |
| Q4 2024 | 1.67% |
| Q3 2024 | -30.85% |
| Q2 2024 | 185.57% |
| Q1 2024 | -24.69% |
| Q4 2023 | -10.03% |
| Q3 2023 | 18.97% |
| Q2 2023 | -38.66% |
| Q1 2023 | 641.34% |
| Q4 2022 | -87.95% |
| Q3 2022 | 19.34% |
| Q2 2022 | 18.69% |
| Q1 2022 | -47.40% |
| Q4 2021 | 13.30% |
| Q3 2021 | -1.28% |
| Q2 2021 | 15.08% |
| Q1 2021 | -19.32% |
| Q4 2020 | 64.11% |
| Q3 2020 | 5.09% |
| Q2 2020 | 18.60% |
| Q1 2020 | 13.61% |
| Q4 2019 | 15.72% |
| Q3 2019 | -4.08% |
| Q2 2019 | -43.01% |
| Q1 2019 | -30.03% |
| Q4 2018 | 28.12% |
| Q3 2018 | -50.28% |
| Q2 2018 | 60.58% |
| Q1 2018 | 13.63% |
| Q4 2017 | 57.23% |
| Q3 2017 | 14.39% |
| Q2 2017 | -6.34% |
| Q1 2017 | -18.03% |
| Q4 2016 | 71.14% |
| Q3 2016 | 9.68% |
| Q2 2016 | -34.48% |
| Q1 2016 | 41.29% |
| Q4 2015 | 23.45% |